Identification
- Generic Name
- Basic Fibroblast Growth Factor
- DrugBank Accession Number
- DB14131
- Background
Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to Fibroblast Growth Factor 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (Fibroblast Growth Factor 1). Although it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Peptides - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Basic astrolial growth factor
- Basic FGF
- Basic fibroblast growth factor, recombinant human, KCB-1
- bFGF
- FGF 2
- Fibroblast growth factor, basic
- Heparin-binding growth factor 2
- KCB-1
- Recombinant human basic fibroblast growth factor, KCB-1
- External IDs
- CCRIS 8682
- FCE 26184
Pharmacology
- Indication
Basic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Cosmeceutical Mask Pack Basic Fibroblast Growth Factor (0.044 mg/22g) + Mecasermin (0.044 mg/22g) + Nepidermin (0.044 mg/22g) + Palmitoyl oligopeptide (0.044 mg/22g) + Prezatide copper (0.22 mg/22g) + Thioredoxin (0.044 mg/22g) Patch Topical YBK Investment, INC 2013-10-21 2013-10-29 US 
Cosmeceutical Mask Pack Basic Fibroblast Growth Factor (0.044 mg/22g) + Mecasermin (0.044 mg/22g) + Nepidermin (0.044 mg/22g) + Palmitoyl oligopeptide (0.044 mg/22g) + Prezatide copper (0.22 mg/22g) + Thioredoxin (0.044 mg/22g) Patch Topical YBK Investment, INC 2013-10-21 Not applicable US Dermaheal Cosmeceutical Mask Pack Plus Basic Fibroblast Growth Factor (0.044 mg/22g) + Mecasermin (0.044 mg/22g) + Nepidermin (0.044 mg/22g) + Palmitoyl oligopeptide (0.044 mg/22g) + Prezatide copper (0.22 mg/22g) + Thioredoxin (0.044 mg/22g) Patch Topical YBK Investment, INC 2013-10-21 Not applicable US Oliglo Golden Radiance Complete Facial Basic Fibroblast Growth Factor (0.001 g/100mL) + Green tea leaf (1.2 g/100mL) Kit; Liquid Topical Dastmalchi LLC 2019-10-30 Not applicable US Pepplus Special Skin Care Lifting Program Basic Fibroblast Growth Factor (0.001 g/100mL) + Green tea leaf (1.28 g/100mL) + Prezatide copper (0.002 g/100mL) Kit Topical Picobio Co., Ltd. 2021-11-02 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Cosmeceutical Mask Pack Basic Fibroblast Growth Factor (0.044 mg/22g) + Mecasermin (0.044 mg/22g) + Nepidermin (0.044 mg/22g) + Palmitoyl oligopeptide (0.044 mg/22g) + Prezatide copper (0.22 mg/22g) + Thioredoxin (0.044 mg/22g) Patch Topical YBK Investment, INC 2013-10-21 2013-10-29 US Cosmeceutical Mask Pack Basic Fibroblast Growth Factor (0.044 mg/22g) + Mecasermin (0.044 mg/22g) + Nepidermin (0.044 mg/22g) + Palmitoyl oligopeptide (0.044 mg/22g) + Prezatide copper (0.22 mg/22g) + Thioredoxin (0.044 mg/22g) Patch Topical YBK Investment, INC 2013-10-21 Not applicable US Dermaheal Cosmeceutical Mask Pack Plus Basic Fibroblast Growth Factor (0.044 mg/22g) + Mecasermin (0.044 mg/22g) + Nepidermin (0.044 mg/22g) + Palmitoyl oligopeptide (0.044 mg/22g) + Prezatide copper (0.22 mg/22g) + Thioredoxin (0.044 mg/22g) Patch Topical YBK Investment, INC 2013-10-21 Not applicable US Oliglo Golden Radiance Complete Facial Basic Fibroblast Growth Factor (0.001 g/100mL) + Green tea leaf (1.2 g/100mL) Kit; Liquid Topical Dastmalchi LLC 2019-10-30 Not applicable US Pepplus Special Skin Care Lifting Program Basic Fibroblast Growth Factor (0.001 g/100mL) + Green tea leaf (1.28 g/100mL) + Prezatide copper (0.002 g/100mL) Kit Topical Picobio Co., Ltd. 2021-11-02 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S3529G9M9V
- CAS number
- 106096-93-9
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Intermittent Claudication / Peripheral Arterial Disease (PAD) 1 2 Completed Treatment Periodontitis 1 2 Completed Treatment Tympanic Membrane Perforation 1 2 Recruiting Treatment Tympanic Membrane Perforation 1 2 Unknown Status Treatment Stomatitis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Patch Topical Kit; liquid Topical Kit Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at June 26, 2018 16:02 / Updated at June 12, 2020 16:53